HUP0300007A2 - Antibody with specificity for colon cancer - Google Patents

Antibody with specificity for colon cancer

Info

Publication number
HUP0300007A2
HUP0300007A2 HU0300007A HUP0300007A HUP0300007A2 HU P0300007 A2 HUP0300007 A2 HU P0300007A2 HU 0300007 A HU0300007 A HU 0300007A HU P0300007 A HUP0300007 A HU P0300007A HU P0300007 A2 HUP0300007 A2 HU P0300007A2
Authority
HU
Hungary
Prior art keywords
binds
active ingredient
specificity
antibody
tumor cells
Prior art date
Application number
HU0300007A
Other languages
English (en)
Inventor
Thomas N Brodin
Pia J Karlstroem
Bo H K Nilson
Lennart G Ohlsson
M Jesper Tordsson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of HUP0300007A2 publication Critical patent/HUP0300007A2/hu
Publication of HUP0300007A3 publication Critical patent/HUP0300007A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Oncology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

A találmány tárgya kötőszerkezet, amely daganatsejtekbe és/vagy azokfelszínéhez kötődik; célszerkezet, amely daganatsejtekben és/vagy adokfelszínén jelenik meg és/vagy expresszálódik; kötőszerkezet, amelyfelismeri és blokkolja az adott célszerkezetet; anyag, amely kötődik aaz adott célszerkezethez, vagy gátolja annak expresszióját;gyógyászati készítmény, amely hatóanyagként tartalmazza akötőszerkezetet, célszerkezeteket vagy anyagokat;oltóanyagkészítmények, amelyek hatóanyagként tartalmazzák acélszerkezeteket; fágszelekciós eljárás; és eljárások rosszindulatúhumán betegségek in vitro és in vivo diagnosztizálására,előrejelzésére és kezelésére, melyek a fentiekben ismertetettanyagokat tartalmazzák. Ó
HU0300007A 2000-02-24 2001-02-23 Antibody with specificity for colon cancer HUP0300007A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0000597A SE0000597D0 (sv) 2000-02-24 2000-02-24 Novel antibody
PCT/SE2001/000395 WO2001062286A1 (en) 2000-02-24 2001-02-23 Novel antibody with specificity for colon cancer

Publications (2)

Publication Number Publication Date
HUP0300007A2 true HUP0300007A2 (en) 2003-05-28
HUP0300007A3 HUP0300007A3 (en) 2005-11-28

Family

ID=20278567

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0300007A HUP0300007A3 (en) 2000-02-24 2001-02-23 Antibody with specificity for colon cancer

Country Status (22)

Country Link
US (1) US7425623B2 (hu)
EP (1) EP1257291A1 (hu)
JP (1) JP2003523213A (hu)
KR (1) KR20020079888A (hu)
CN (1) CN1406136A (hu)
AU (1) AU775876B2 (hu)
BR (1) BR0108609A (hu)
CA (1) CA2400661A1 (hu)
EE (1) EE200200473A (hu)
HK (1) HK1052648A1 (hu)
HU (1) HUP0300007A3 (hu)
IL (1) IL151325A0 (hu)
MX (1) MXPA02008315A (hu)
NO (1) NO20023670L (hu)
NZ (1) NZ520523A (hu)
PL (1) PL356386A1 (hu)
RU (1) RU2268068C2 (hu)
SE (1) SE0000597D0 (hu)
SK (1) SK11982002A3 (hu)
WO (1) WO2001062286A1 (hu)
YU (1) YU63702A (hu)
ZA (1) ZA200206039B (hu)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1403283A4 (en) * 2001-06-12 2006-05-10 Greenpeptide Co Ltd TUMOR ANTIGEN
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
CN1303105C (zh) * 2003-12-08 2007-03-07 陈志南 抗人大肠癌单克隆抗体CAb—2轻、重链可变区基因及其应用
CA2652703C (en) * 2006-06-07 2018-08-28 Bioalliance C.V. Antibodies recognizing a carbohydrate containing epitope on cd-43 and cea expressed on cancer cells and methods using same
EP2048241B1 (en) * 2007-10-08 2012-07-25 Sividon Diagnostics GmbH Method employing GAPDH as molecular markers for cancer prognosis
HUE026846T2 (hu) * 2007-12-18 2016-08-29 Bioalliance Cv Antitestek, amelyek felismernek ráksejteken expresszált CD43-on és CEA-n jelenlévõ szénhidrát-tartalmú epitópot, és eljárások alkalmazásukra
JP5515071B2 (ja) * 2008-09-01 2014-06-11 国立大学法人名古屋大学 抗がん剤の作用増強剤及びその利用、並びにがん患者の予後推定用バイオマーカー及びその利用
FR2945952B1 (fr) * 2009-05-27 2013-10-04 Univ Claude Bernard Lyon Anticorps anti-ck8 pour utilisation comme medicament.
CN117737190A (zh) * 2023-12-15 2024-03-22 承德医学院 一种检测结直肠癌肿瘤细胞相关微生物的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798257A (en) * 1990-07-09 1998-08-25 Research Corporation Technologies, Inc. Nucleic acid encoding human MTS-1 protein
US5994088A (en) * 1991-03-08 1999-11-30 Board Of Trustees Of The University Of Illinois Methods and reagents for preparing and using immunological agents specific for P-glycoprotein
WO1994003205A1 (en) * 1992-08-07 1994-02-17 Cytel Corporation Hla binding peptides and their uses
US5972643A (en) * 1994-06-17 1999-10-26 Fred Hutchinson Cancer Research Center Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
AU721129B2 (en) * 1996-01-08 2000-06-22 Genentech Inc. WSX receptor and ligands
WO1998003411A1 (fr) 1996-07-18 1998-01-29 Montania Bouchon avec recipient auxiliaire et procede de realisation
DK0934526T3 (da) * 1996-10-08 2003-05-05 Bisys B V U Fremgangsmåder og midler til udvælgelse af peptider og proteiner, der har specifik affinitet til et mål
SE9700291D0 (sv) * 1997-01-31 1997-01-31 Pharmacia & Upjohn Ab Selection method and prodcts resulting therefrom
ATE299938T1 (de) * 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
EP1009819A1 (en) * 1997-08-29 2000-06-21 Selective Genetics, Inc. Methods using phage display for selecting internalizing ligands for gene delivery
DE19739525A1 (de) * 1997-09-09 1999-09-30 Heinrich Abbrederis Die Vorrichtung T.C.Reinigungskopf ermöglicht die Reinigung, Schmierung und Konservierung von Ketten im eingebauten und ausgebauten Zustand unter minimalen Platzverhältnissen
CA2253633A1 (en) * 1997-12-03 1999-06-03 Boehringer Mannheim Corporation Complex specific antibodies, method of preparation and uses thereof
IL144559A0 (en) * 1999-03-01 2002-05-23 Genentech Inc Antibodies for cancer therapy and diagnosis

Also Published As

Publication number Publication date
RU2268068C2 (ru) 2006-01-20
HK1052648A1 (zh) 2003-09-26
EP1257291A1 (en) 2002-11-20
PL356386A1 (en) 2004-06-28
AU3629401A (en) 2001-09-03
ZA200206039B (en) 2003-07-29
HUP0300007A3 (en) 2005-11-28
JP2003523213A (ja) 2003-08-05
CN1406136A (zh) 2003-03-26
NZ520523A (en) 2004-08-27
NO20023670D0 (no) 2002-08-02
KR20020079888A (ko) 2002-10-19
IL151325A0 (en) 2003-04-10
RU2002125386A (ru) 2004-03-20
US20030176661A1 (en) 2003-09-18
AU775876B2 (en) 2004-08-19
EE200200473A (et) 2004-02-16
SK11982002A3 (sk) 2003-03-04
MXPA02008315A (es) 2002-12-09
BR0108609A (pt) 2002-11-19
WO2001062286A1 (en) 2001-08-30
YU63702A (sh) 2006-01-16
CA2400661A1 (en) 2001-08-30
SE0000597D0 (sv) 2000-02-24
NO20023670L (no) 2002-08-23
US7425623B2 (en) 2008-09-16

Similar Documents

Publication Publication Date Title
WO2004113571A3 (en) Prostate specific genes and the use thereof as targets for prostate cancer therapy and diagnosis
CY1110256T1 (el) Διαμεμβρανικο αντιγονο λεκτινης τυπου c εκφραζομενο σε καρκινο στον προστατη ανθρωπου και χρησεις αυτου
EP1350085A4 (en) MONOCLONAL ANTIBODIES AND CELL SURFACE ANTIGENS FOR THE DETECTION AND TREATMENT OF SMALL CELL LUNG CANCER (SCLC)
BRPI0207961A8 (pt) Uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
WO2002046477A3 (en) Endogenous retroviruses up-regulated in prostate cancer
WO2002032292A3 (en) Methods for development and use of diagnostic and therapeutic agents
TR200201442T2 (tr) Ağrı hafifletme, kemik kanseri terapisi ve kemik yüzeyinin sağlıklı tutulması için kireçlenmiş hedef dokulara yönelik radyum-223 hazırlanması ve kullanımı.
WO2002002147A3 (en) Isolation of a cell-specific internalizing peptide that infiltrates tumor tissue for targeted drug delivery
WO2005055936A3 (en) Methods of killing tumor cells by targeting internal antigens exposed on apoptotic tumor cells
WO2005054295A8 (en) Therapeutic and diagnostic anti-hsp 70 antibodies
HUP0300007A2 (en) Antibody with specificity for colon cancer
HUP9901908A2 (hu) p16 Expressziós konstrukciók és alkalmazásuk rákterápiában
NO932101D0 (no) Polypeptidmateriale som er anvendelig ved terapeutisk behandling av mennesker
WO2002053700A3 (en) Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
ES2114615T3 (es) Nueva sonda para el diagnostico de tumores o la terapia de tumores.
WO2001077168A3 (en) Compositions and methods for the therapy and diagnosis of lung cancer
ATE417054T1 (de) Steuerbare phosphofructokinase und der warburg effekt
WO2001090152A3 (en) Compositions and methods for the therapy and diagnosis of breast cancer
BRPI0409475A (pt) inibição de vav na rejeição de enxerto
Requena et al. Microcystic adnexal carcinoma
WO2004016813A3 (en) Hnf1 alpha as a tumor suppressor gene, and diagnostic and therapeutic applications thereof
DE60108622D1 (de) Arzneimittel zur anwendung bei tumorkrankheiten welches ro5-4864 und ein apoptoseauslöser enthält
WO2003042700A3 (en) Breast cancer associated polypeptide
WO2004078123A3 (en) Early prostate cancer antigens (epca), polynucleotide sequences encoding them, and their use
ES2170479T3 (es) Agente viral terapeutico que detiene el desarrollo de tumores.

Legal Events

Date Code Title Description
FA9A Lapse of provisional patent protection due to relinquishment or protection considered relinquished